Trupanion, Inc. (NASDAQ:TRUP) insider Darryl Rawlings sold 3,500 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $34.08, for a total transaction of $119,280.00. Following the transaction, the insider now owns 1,386,476 shares in the company, valued at approximately $47,251,102.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Darryl Rawlings also recently made the following trade(s):
- On Wednesday, December 27th, Darryl Rawlings sold 3,500 shares of Trupanion stock. The shares were sold at an average price of $30.11, for a total transaction of $105,385.00.
- On Wednesday, December 13th, Darryl Rawlings sold 3,500 shares of Trupanion stock. The shares were sold at an average price of $30.10, for a total transaction of $105,350.00.
Trupanion, Inc. (NASDAQ:TRUP) traded down $0.26 during midday trading on Friday, hitting $33.83. 118,500 shares of the stock were exchanged, compared to its average volume of 219,933. The company has a current ratio of 1.87, a quick ratio of 1.87 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1,024.06, a PE ratio of -375.85 and a beta of 0.14. Trupanion, Inc. has a 12-month low of $13.88 and a 12-month high of $35.07.
A number of research analysts have weighed in on the stock. BidaskClub cut shares of Trupanion from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. CL King assumed coverage on shares of Trupanion in a research report on Tuesday, November 21st. They set a “neutral” rating on the stock. Zacks Investment Research upgraded shares of Trupanion from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Wednesday, November 8th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $35.00 price objective (up previously from $29.00) on shares of Trupanion in a research report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $28.83.
Several hedge funds and other institutional investors have recently bought and sold shares of TRUP. JPMorgan Chase & Co. bought a new position in shares of Trupanion in the third quarter worth about $143,000. Voya Investment Management LLC bought a new position in shares of Trupanion in the second quarter worth about $215,000. Oppenheimer Asset Management Inc. bought a new position in shares of Trupanion in the third quarter worth about $221,000. Wells Fargo & Company MN grew its holdings in shares of Trupanion by 13.5% in the second quarter. Wells Fargo & Company MN now owns 11,261 shares of the financial services provider’s stock worth $252,000 after purchasing an additional 1,342 shares during the last quarter. Finally, Nationwide Fund Advisors grew its holdings in shares of Trupanion by 52.7% in the second quarter. Nationwide Fund Advisors now owns 12,694 shares of the financial services provider’s stock worth $284,000 after purchasing an additional 4,380 shares during the last quarter. Hedge funds and other institutional investors own 63.25% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/01/19/trupanion-inc-trup-insider-darryl-rawlings-sells-3500-shares.html.
Trupanion Company Profile
Trupanion, Inc provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The Company operates in two business segments: subscription business and other business. The subscription business segment includes monthly subscriptions for its medical plan, which are marketed to consumers.
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.